PL3524250T3 - Kompozycja farmaceutyczna zawierająca inhibitor neutralnej endopeptydazy (NEP) i pochodną estru azylsartanu oraz jej zastosowanie w leczeniu chorób sercowo-naczyniowych - Google Patents

Kompozycja farmaceutyczna zawierająca inhibitor neutralnej endopeptydazy (NEP) i pochodną estru azylsartanu oraz jej zastosowanie w leczeniu chorób sercowo-naczyniowych

Info

Publication number
PL3524250T3
PL3524250T3 PL17857826.6T PL17857826T PL3524250T3 PL 3524250 T3 PL3524250 T3 PL 3524250T3 PL 17857826 T PL17857826 T PL 17857826T PL 3524250 T3 PL3524250 T3 PL 3524250T3
Authority
PL
Poland
Prior art keywords
nep
inhibitor
pharmaceutical composition
cardiovascular diseases
ester derivative
Prior art date
Application number
PL17857826.6T
Other languages
English (en)
Inventor
Chaodong Wang
Yongkai CHEN
Liu HU
Xian ZENG
Daiwu KANG
Original Assignee
Wuhan Ll Science And Technology Development Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan Ll Science And Technology Development Co., Ltd. filed Critical Wuhan Ll Science And Technology Development Co., Ltd.
Publication of PL3524250T3 publication Critical patent/PL3524250T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL17857826.6T 2016-10-08 2017-09-27 Kompozycja farmaceutyczna zawierająca inhibitor neutralnej endopeptydazy (NEP) i pochodną estru azylsartanu oraz jej zastosowanie w leczeniu chorób sercowo-naczyniowych PL3524250T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610887841 2016-10-08
PCT/CN2017/103651 WO2018064945A1 (zh) 2016-10-08 2017-09-27 药物组合物

Publications (1)

Publication Number Publication Date
PL3524250T3 true PL3524250T3 (pl) 2025-11-12

Family

ID=61831617

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17857826.6T PL3524250T3 (pl) 2016-10-08 2017-09-27 Kompozycja farmaceutyczna zawierająca inhibitor neutralnej endopeptydazy (NEP) i pochodną estru azylsartanu oraz jej zastosowanie w leczeniu chorób sercowo-naczyniowych

Country Status (8)

Country Link
US (1) US11096928B2 (pl)
EP (1) EP3524250B1 (pl)
CN (1) CN109803657B (pl)
DK (1) DK3524250T3 (pl)
ES (1) ES3041628T3 (pl)
FI (1) FI3524250T3 (pl)
PL (1) PL3524250T3 (pl)
WO (1) WO2018064945A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11161803B2 (en) * 2017-04-28 2021-11-02 Wuhan Ll Science And Technology Development Co., Ltd. Ammonium carboxylate compound, crystalline form, amorphous form and preparation method thereof
WO2019085983A1 (zh) * 2017-11-03 2019-05-09 武汉朗来科技发展有限公司 低杂质含量苯并咪唑衍生物的制备方法
CN110237071B (zh) * 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用
CN110237072B (zh) * 2018-03-09 2022-03-25 武汉朗来科技发展有限公司 药物组合物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1256692A (en) * 1991-02-06 1992-09-07 Schering Corporation Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
DK1467728T3 (da) 2002-01-17 2007-12-27 Novartis Ag Farmaceutiske sammensætninger indeholdende valsartan og NEP-inhibitorer
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
RU2008122712A (ru) * 2005-11-08 2009-12-20 Новартис АГ (CH) Комбинация органических соединений
CN103709154B (zh) 2012-09-28 2016-06-15 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
CN104774196B (zh) * 2014-01-09 2017-11-10 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
CN105693543B (zh) * 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN105837464A (zh) 2015-01-15 2016-08-10 四川海思科制药有限公司 沙库比曲钠的晶型及其制备方法和用途
EP3461822B1 (en) * 2016-07-11 2022-11-02 Wuhan LL Science And Technology Development Co., Ltd. Crystalline form of chemical compound, and preparation method, composition, and application thereof

Also Published As

Publication number Publication date
US20200038379A1 (en) 2020-02-06
CN109803657B (zh) 2022-07-29
FI3524250T3 (fi) 2025-08-29
WO2018064945A1 (zh) 2018-04-12
EP3524250B1 (en) 2025-07-16
DK3524250T3 (da) 2025-09-08
CN109803657A (zh) 2019-05-24
EP3524250A1 (en) 2019-08-14
US11096928B2 (en) 2021-08-24
EP3524250A4 (en) 2020-05-20
ES3041628T3 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
IL263082B (en) New compounds as ototaxin inhibitors and pharmaceutical preparations containing them
IL257521A (en) Compositions comprising a pi3k inhibitor and an hdac inhibitor
IL262961A (en) Therapeutic uses of a c-raf inhibitor
PL3331864T3 (pl) Związki pochodne 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 oraz zawierająca je kompozycja farmaceutyczna
EP3673907A4 (en) CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT
DK3387134T3 (da) Fremgangsmåder og sammensætninger til øget nukleasemedieret genommodifikation og reducerede virkninger uden for målstedet
CA3301698A1 (en) TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES
EP3389672A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF LIVER DISEASES
EP3371152A4 (en) COMPOSITIONS WITH AN INHIBITOR OF LYSINE-SPECIFIC DEMETHYLASE-1
IL257499A (en) Compounds containing as phosphoinositide 3-kinase inhibitors and a second antiproliferative factor
EP3336090A4 (en) INHIBITOR OF IRAQ4 AND ITS USE
EP3171859A4 (en) Pharmaceutical composition comprising 5alpha-reductase inhibitor
PL3302519T3 (pl) Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu ostrej choroby przeszczep przeciwko gospodarzowi
EP3386594A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF MEDICAMENT-TOLERANT GLIOBLASTOM
EP3132795A4 (en) Composition for preventing or treating fatty liver diseases
PL3524250T3 (pl) Kompozycja farmaceutyczna zawierająca inhibitor neutralnej endopeptydazy (NEP) i pochodną estru azylsartanu oraz jej zastosowanie w leczeniu chorób sercowo-naczyniowych
HK1256042A1 (zh) 用於治疗糖尿病周围神经病变的hdac抑制剂
EP3105234A4 (en) Compositions and methods for treating diabetes and liver diseases
HK1255204A1 (zh) 含硫化合物溶剂
SG11201702389XA (en) Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor
EP3256143A4 (en) Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof and methods of using the same
EP3242886A4 (en) Formulation of mk2 inhibitor peptides
SG11201605956RA (en) Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
PT3511774T (pt) Composição de revestimento fotoprotetor de trabalho negativo para ablação laser e processo utilizando-a
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them